Every capitalist dreams of speculation in the "gold" sector. Long-term transactions are not of great interest to investors, who are aimed at quick and high profits. The field of biotechnology itself is long-term, sustainable and, as the figures show, promising. Risks in this sector are minimized by carrying out three types of tests: preclinical, clinical and commercial.
Biotechnology is becoming a calm haven for deposits. During the financial crisis of 2008, the American stock market lost about 50%, while biotech stock exchanges lost only about 20%.
